P

eter Larsen watched a discouraging cycle of pharmaceutical companies touting a new treatment for Alzheimer’s only to be followed by a failed drug trial. So he considered another approach.

The Duke University biologist, who studies mouse lemurs that have symptoms resembling Alzheimer’s, co-authored a paper with a Duke neurologist that considers whether the science behind failed Alzheimer’s drugs incorrectly equated the buildup of amyloid plaques — a waxy protein inside the brain — with a cause of the memory-destroying disease rather than a symptom. Called the “amyloid hypothesis,” this line of thinking has been called into question with the recent failures of drugs targeting amyloid.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.